Abstract
The vitamin D receptor (VDR) is an endocrine member of the nuclear receptor superfamily and binds the biologically most active vitamin D metabolite, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3). The VDR ligandbinding domain is a molecular switch, since its ligand-triggered interactions with corepressor and coactivator proteins are the central molecular events of nuclear 1α,25(OH)2D3 signaling. 1α,25(OH)2D3 analogues have been developed with the goal to improve the biological profile of the natural hormone for a therapeutic application either in hyperproliferative diseases, such as psoriasis and different types of cancer, or in bone disorders, such as osteoporosis. Most of the analogues described to date are agonists, with a few having been identified as antagonists. Only the two side chain analogue Gemini and some of its derivatives act under restricted conditions as inverse agonists. In this review we discuss the molecular mechanisms of these different type of analogues based on crystal structure data, molecular dynamics simulations and biochemical assays.
Keywords: Nuclear receptor signaling, vitamin D, vitamin D analogues, vitamin D receptor, coactivator proteins, corepressor proteins
Current Topics in Medicinal Chemistry
Title: Detailed Molecular Understanding of Agonistic and Antagonistic Vitamin D Receptor Ligands
Volume: 6 Issue: 12
Author(s): Carsten Carlberg and Ferdinand Molnar
Affiliation:
Keywords: Nuclear receptor signaling, vitamin D, vitamin D analogues, vitamin D receptor, coactivator proteins, corepressor proteins
Abstract: The vitamin D receptor (VDR) is an endocrine member of the nuclear receptor superfamily and binds the biologically most active vitamin D metabolite, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3). The VDR ligandbinding domain is a molecular switch, since its ligand-triggered interactions with corepressor and coactivator proteins are the central molecular events of nuclear 1α,25(OH)2D3 signaling. 1α,25(OH)2D3 analogues have been developed with the goal to improve the biological profile of the natural hormone for a therapeutic application either in hyperproliferative diseases, such as psoriasis and different types of cancer, or in bone disorders, such as osteoporosis. Most of the analogues described to date are agonists, with a few having been identified as antagonists. Only the two side chain analogue Gemini and some of its derivatives act under restricted conditions as inverse agonists. In this review we discuss the molecular mechanisms of these different type of analogues based on crystal structure data, molecular dynamics simulations and biochemical assays.
Export Options
About this article
Cite this article as:
Carlberg Carsten and Molnar Ferdinand, Detailed Molecular Understanding of Agonistic and Antagonistic Vitamin D Receptor Ligands, Current Topics in Medicinal Chemistry 2006; 6 (12) . https://dx.doi.org/10.2174/156802606777864908
DOI https://dx.doi.org/10.2174/156802606777864908 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
1α ,25(OH)2-Vitamin D3 and 17β-Estradiol: Two Steroid Partners Acting in Skeletal Muscle
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Is Technical-Grade Chlordane an Obesogen?
Current Medicinal Chemistry Estrogen Receptor Alpha: Impact of Ligands on Intracellular Shuttling and Turnover Rate in Breast Cancer Cells
Current Cancer Drug Targets IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review
Recent Patents on Anti-Cancer Drug Discovery Drugs and Foods for Chronic Subclinical Inflammation in Humans
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets Regeneration of Pancreatic β-Cells in vivo as a Potential Therapeutic Approach for Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry The Two Faces of Protein Palmitoylation in Islet β-Cell Function: Potential Implications in the Pathophysiology of Islet Metabolic Dysregulation and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Synthesis and Evaluation of Amido-Deoxyestradiol Derivatives as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 12
Current Enzyme Inhibition Recent Advances in the Development of Antimicrobial Peptides (AMPs): Attempts for Sustainable Medicine?
Current Medicinal Chemistry Environmental Contaminants Perturb Fragile Protein Assemblies and Inhibit Normal Protein Function
Current Chemical Biology Prostate Cancer with Variants in CYP17 and UGT2B17 Genes: A Meta-Analysis
Protein & Peptide Letters Androgen Receptor Antagonists in the Treatment of Prostate Cancer
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics Improving Health Care for Children with Chronic Conditions: Toward a “Wholistic” Approach
Current Pediatric Reviews The Effects of Dietary Supplements that Overactivate the Nrf2/ARE System
Current Medicinal Chemistry Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety